Tirzepatide is the first single molecule engineered to switch on two different incretin receptors at once. This article examines what researchers understand about that dual GIP and GLP-1 receptor mechanism, how it was designed, and what the clinical record does and does not yet establish.

GIP and GLP-1: the two incretin hormones

The rationale behind tirzepatide begins with the incretin effect — the observation that oral glucose triggers a larger insulin response than the same glucose given intravenously. Two gut hormones account for most of that effect: glucose-dependent insulinotropic polypeptide (GIP), secreted by intestinal K cells, and glucagon-like peptide-1 (GLP-1), secreted by L cells. Both are released after nutrient ingestion and both act through G-protein-coupled receptors to raise intracellular cyclic AMP in pancreatic β cells, amplifying insulin secretion only when glucose is elevated.¹

Although the two hormones share an insulinotropic role, their broader biology diverges in ways that matter for a co-agonist. Reviews of incretin physiology note that GLP-1 suppresses glucagon secretion, slows gastric emptying and reduces food intake through central pathways, whereas GIP has a more complex profile: it can enhance the glucagon response after meals, and in adipose tissue it has been linked to lipid handling and fat deposition rather than suppression of intake.¹ In tissues beyond the pancreas — bone, brain and fat — the receptors are expressed in different patterns, which is part of why combining the two signals was considered scientifically interesting rather than merely additive.

Critically, GIP was for years thought to have little therapeutic value in type 2 diabetes because supraphysiological GIP infusion failed to boost insulin secretion in affected individuals, an apparent loss of GIP responsiveness in the diabetic state.¹ That paradox — a hormone that looks inert on its own yet appears to add value when paired with GLP-1 activity — frames much of the research discussion around tirzepatide.

Designing one molecule for two receptors

Tirzepatide (development code LY3298176) was built as a 39-amino-acid synthetic peptide based on the native GIP sequence, modified with a C20 fatty diacid moiety to enable albumin binding and once-weekly pharmacokinetics.² The discovery work characterized the molecule in receptor-signaling assays and in rodent models before human testing. In cell lines, the peptide activated both GIPR and GLP-1R signaling; in mice it improved glucose tolerance in a manner dependent on both receptors, and with chronic administration it lowered body weight and food intake to a greater degree than a GLP-1 receptor agonist comparator.²

The preclinical-to-clinical translation was a deliberate test of a hypothesis: that adding GIP receptor agonism to the established metabolic action of GLP-1 receptor agonism could shift the balance of glucose control and weight change. The first-in-human phase 1 program reported dose-dependent reductions in fasting serum glucose and body weight, with gastrointestinal events (nausea, vomiting, diarrhea) as the dominant tolerability signal — a profile broadly familiar from the GLP-1 receptor agonist class.² This mechanistic lineage is what distinguishes tirzepatide from single-receptor agents such as semaglutide, and it also motivated the later triple-agonist candidates like retatrutide that add glucagon receptor activity.

The dual-action mechanism, step by step

Mechanistic and review literature describes tirzepatide's action as the convergence of several receptor-mediated effects rather than a single pathway.⁴ The components below are those most consistently reported in preclinical models and mechanistic studies; the human contribution of each is discussed in the section on contested evidence.

Glucose-dependent insulin secretion

Activation of GIPR and GLP-1R on pancreatic β cells raises cyclic AMP and augments insulin release in proportion to the prevailing glucose level. Because the effect is glucose-dependent, the mechanism carries a low intrinsic hypoglycemia signal when used as monotherapy in models, a property inherited from the incretin biology itself.¹

Glucagon dynamics

GLP-1 receptor activation is associated with suppression of glucagon secretion, which lowers hepatic glucose output. The picture is more nuanced for the GIP arm, since GIP has been described as enhancing rather than suppressing the postprandial glucagon response; the net effect of the co-agonist on glucagon is an area of active mechanistic study.⁴

Gastric emptying and food intake

Slowed gastric emptying and reduced appetite are attributed largely to GLP-1 receptor signaling, including at central sites that regulate intake. Both receptors are expressed in brain regions involved in energy balance, and mechanistic reviews propose that the combined central signal contributes to the weight changes observed in trials.⁴

Adipose tissue and insulin sensitivity

GIP receptor engagement has been linked in preclinical work to adipose-tissue metabolism and insulin sensitivity. In mechanistic comparisons, tirzepatide has been reported to improve markers of insulin sensitivity and insulin secretory response to a greater degree than a selective GLP-1 receptor agonist, an observation used to argue that the GIP component adds a distinct metabolic dimension.⁴

Imbalanced and biased receptor pharmacology

One of the more precise findings about tirzepatide comes from quantitative receptor-occupancy and signaling work. Rather than engaging both receptors equally, the molecule shows a greater degree of engagement at GIPR than at GLP-1R at clinically relevant doses — described in the literature as an imbalanced mechanism of action.³

Beyond imbalance, the peptide also displays biased agonism at the GLP-1 receptor. Signaling studies report that at GLP-1R, tirzepatide favors cyclic AMP generation over β-arrestin recruitment and drives weaker receptor internalization than native GLP-1.³ In primary islet experiments, β-arrestin1 limited the insulin response to GLP-1 but not to GIP or to tirzepatide, which the authors interpret as a way the biased profile could sustain insulin secretion.³ At the GIP receptor, by contrast, tirzepatide behaved much like native GIP. This combination — imbalance toward GIPR plus distinct GLP-1R signaling — is the pharmacological hypothesis offered for why the agent's clinical profile differs from selective GLP-1 receptor agonists.

What the SURPASS clinical record shows

The human data come primarily from the SURPASS phase 3 program in people with type 2 diabetes, which tested tirzepatide at 5, 10 and 15 mg once weekly against several comparators.⁸ The table below summarizes reported outcomes from representative trials; values are trial-level results in the study populations, not projections for any individual.

In SURPASS-2, tirzepatide was reported non-inferior and superior to once-weekly semaglutide 1 mg on the primary HbA1c endpoint, with larger accompanying weight reductions and a gastrointestinal adverse-event profile similar between the two agents.⁵ In SURPASS-3, all three tirzepatide doses produced greater HbA1c and weight reductions than titrated insulin degludec, with a lower reported rate of hypoglycemia.⁶ In SURPASS-5, adding tirzepatide to titrated insulin glargine produced statistically significant HbA1c reductions versus placebo at 40 weeks.⁷

Post hoc analyses have probed sub-populations and response patterns. In a pooled subgroup of participants aged 65 years or older with a body-mass index below 30 kg/m², HbA1c reductions of roughly 1.97–2.10% were reported without an increase in hypoglycemia relative to the overall cohort.⁹ A separate pooled analysis found that early reductions in fasting serum glucose or body weight were associated with better metabolic outcomes at week 40/42, though non-early responders also showed clinically meaningful changes — a signal the authors frame as a potential aid to treatment individualization rather than a fixed rule.¹⁰

Where the evidence is still contested

The most honest characterization of tirzepatide's mechanism is that the clinical outcomes are robust while the causal story is incomplete. Review literature raises two specific unresolved questions.⁴ First, although GIP reduces food intake and body weight in rodents, that effect has not been demonstrated in humans, so the extent to which the GIP arm drives the observed weight changes in people is uncertain. Second, it remains to be shown that GIP receptor agonism can improve insulin secretion in individuals with type 2 diabetes, given earlier evidence that they are relatively unresponsive to GIP.⁴

There is also ongoing scientific debate about whether beneficial GIP receptor pharmacology is best achieved through agonism or, counterintuitively, antagonism — a controversy that the imbalanced, biased profile of tirzepatide does not by itself settle.³ For a research audience, this uncertainty is the point of interest: tirzepatide is a tool for interrogating incretin biology, and its molecular behavior at each receptor is exactly what makes it a useful reference compound in mechanistic and comparative studies.

Regulatory status and research use

As a pharmaceutical, tirzepatide is approved by regulators including in the United States, the European Union and elsewhere for type 2 diabetes, and it has been the subject of the SURPASS program summarized above.⁸ That regulatory status applies to the manufactured, prescription pharmaceutical product used under medical supervision.

The material supplied by Qovigen is a research-use-only reference compound. It is intended for in-vitro and laboratory investigation — receptor pharmacology, assay development, comparative studies against agents such as semaglutide and retatrutide, and analytical work — and it is not a drug product, not for human or veterinary administration, and not for diagnosis or treatment. Researchers evaluating purity-dependent endpoints should rely on batch-specific analytical documentation rather than on clinical literature, which describes a differently manufactured pharmaceutical.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.